AIM ImmunoTech Share Holder Equity 2010-2025 | AIM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AIM ImmunoTech share holder equity from 2010 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AIM ImmunoTech share holder equity from 2010 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.7B
Zoetis (ZTS)	$66.3B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$43.3B
BeOne Medicines - (ONC)	$32.9B
Sandoz Group AG (SDZNY)	$25.9B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.3B
Neurocrine Biosciences (NBIX)	$13.5B
United Therapeutics (UTHR)	$12.7B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.6B
Grifols, S.A (GRFS)	$7.5B
Corcept Therapeutics (CORT)	$7.4B
Ionis Pharmaceuticals (IONS)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B